|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-9-4
|
|
pubmed:abstractText |
The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease. Thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (VEGF)-induced angiogenesis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10740
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
758-65
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12209719-Administration, Oral,
pubmed-meshheading:12209719-Adult,
pubmed-meshheading:12209719-Aged,
pubmed-meshheading:12209719-Angiogenesis Inhibitors,
pubmed-meshheading:12209719-Carcinoma, Renal Cell,
pubmed-meshheading:12209719-Disease-Free Survival,
pubmed-meshheading:12209719-Drug Administration Schedule,
pubmed-meshheading:12209719-Female,
pubmed-meshheading:12209719-Humans,
pubmed-meshheading:12209719-Interleukin-2,
pubmed-meshheading:12209719-Kidney Neoplasms,
pubmed-meshheading:12209719-Male,
pubmed-meshheading:12209719-Middle Aged,
pubmed-meshheading:12209719-Neoplasm Metastasis,
pubmed-meshheading:12209719-Pilot Projects,
pubmed-meshheading:12209719-Survival Analysis,
pubmed-meshheading:12209719-Thalidomide
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
|
|
pubmed:affiliation |
Department of Genitourinary Medical Oncology, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. ddaliani@notes.mdacc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|
